Navigation Links
Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Date:8/19/2007

WAYNE, N.J., Aug. 3 /PRNewswire/ -- Patients treated with Betaseron(R) (interferon beta-1b) shortly after their first clinical MS event or "attack" showed a 40 percent lower risk of developing confirmed disability progression compared to patients in whom treatment was delayed. The results-which were fast-tracked and published in The Lancet this week-provide the first controlled evidence that delaying Betaseron treatment has an effect on later accumulation of disability, as observed over the three-year study period. No other MS therapy has demonstrated this effect in this early patient population.

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/bayer/29192/

The BENEFIT study (Betaseron in Newly Emerging multiple sclerosis For Initial Treatment), sponsored by Bayer HealthCare, compared Betaseron treatment initiated after a first clinical event with delayed treatment. The study was conducted at 98 sites in 20 countries and included a total of 468 patients.

In the study, investigators measured progression of patient disability using a validated scale called EDSS (Expanded Disability Status Scale).(1) Disability progression was defined as an increase in a patient's EDSS score by at least one point that was confirmed after six months. A confirmed increase by one point in the EDSS scale can be an important and robust predictor of permanent and severe disability later in the disease.(2)

"This research has important implications for the way we treat MS because, for the first time, we have controlled data that irrefutably demonstrates the value of early intervention with effective treatment for patients," said Dr. Ludwig Kappos, Professor of Neurology and Clinical Neuroimmunology at the University of Basel, Switzerland and lead investigator of the BENEFIT study. "These findings support the decision to actively treat patients at the first clinical sig
'/>"/>

SOURCE Bayer

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
2. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
3. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
4. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
5. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
6. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
7. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
10. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
(Date:4/22/2014)... cancers are small cell lung cancers (SCLC), which ... However, researchers at Virginia Commonwealth University Massey Cancer ... leading to this resistance that may lead to ... mediating B-cell lymphoma 2 (Bcl-2) family proteins, which ... their function, this family of proteins can trigger ...
(Date:4/22/2014)... for Molecular Pathology (AMP) released a report today ... on recommendations for a molecular diagnostics curriculum at ... The report was prepared by the Medical Laboratory ... Training and Education Committee. "Our goal was to ... laboratory scientists appropriately in order to manage the ...
(Date:4/22/2014)... and rabbits, Johns Hopkins scientists have found a way ... preventing the development of atherosclerosis, the main cause of ... death among humans. The condition develops when fat builds ... narrowed and hardened, greatly reducing their ability to feed ... , In a series of experiments, described April 7 ...
(Date:4/22/2014)... in German . ... molecules, but their mode of action is complex: In ... and behavior, while at high concentrations they can cause ... analyze how redox signaling unfolds in single cells and ... been developed jointly by the teams of LMU Professor ...
(Date:4/22/2014)... a new RAND study concludes that U.S. policy makers ... device makers to develop products that produce more value. ... use, a new study suggests the study identifies options ... in the first place. The aim is to help ... health as possible and to ensure that costlier advances ...
Breaking Medicine News(10 mins):Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:Neuroimaging: Live from inside the cell 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3
... disease are receiving implantable cardioverter-defibrillators (ICDs) to maintain proper ... the 1980s, but little is known about how well ... 1 percent of recipients. A report in the April ... the largest pediatric experience to date. It finds the ...
... In a major step toward a practical energy ... development of a new generation of sub-microscopic nanomotors that ... motors. Their study is scheduled for the May 27 ... the new study, Joseph Wang and colleagues point out ...
... Campaign Encourages Consumers to Get Active and Give Back By Logging Miles ... ... A healthy lifestyle is always,important and to encourage consumers to get active, ... Breast,Cancer Organization with a donation of up to $200,000. Running from May ...
... Management to Host Conference Call Today at 11:30 a.m. ET ... a provider of liquid nutritional, functional foods, beverages and,nutritional supplements, ... 2008., Financial and operational highlights for First Quarter ... year period to $1.6 million -- Gross profit was ...
... Fla., May 1 Blue Cross and ... David Pizzo has been appointed Market,President - ... http://www.newscom.com/cgi-bin/prnh/20080501/CLTH034 ), (Logo: http://www.newscom.com/cgi-bin/prnh/20000427/BLUELOGOA ... ), Pizzo has served in a ...
... Mich., May 1 Perrigo Company,(Nasdaq: PRGO ... Directors declared a,quarterly dividend of $0.05 per share, ... on May 25, 2008., Perrigo Company is ... distributes over-the-counter (OTC) and prescription,pharmaceuticals, nutritional products, active ...
Cached Medicine News:Health News:Largest study to date finds benefits of ICDs in children 2Health News:Bumble Bee Foods Launches BeeWell Miles; An Interactive Health and Wellness Program Benefitting the Y-Me National Breast Cancer Foundation 2Health News:Bumble Bee Foods Launches BeeWell Miles; An Interactive Health and Wellness Program Benefitting the Y-Me National Breast Cancer Foundation 3Health News:XELR8 Holdings Announces Record First Quarter Revenue 2Health News:XELR8 Holdings Announces Record First Quarter Revenue 3Health News:XELR8 Holdings Announces Record First Quarter Revenue 4Health News:XELR8 Holdings Announces Record First Quarter Revenue 5Health News:XELR8 Holdings Announces Record First Quarter Revenue 6Health News:XELR8 Holdings Announces Record First Quarter Revenue 7Health News:XELR8 Holdings Announces Record First Quarter Revenue 8Health News:David Pizzo Appointed Blue Cross and Blue Shield of Florida Market President - West Florida 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: